Compare Diageo plc (DEO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Gilead Sciences, Inc. — how do they compare? Diageo plc trades at $87.58 (market cap $47.54B), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 3.8× Diageo plc's market cap, and Diageo plc pays the higher dividend (2.36%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Gilead Sciences, Inc. for 111 Days on average.
| DEO | GILD | |
|---|---|---|
Market Cap | $47.54B | $182.09B |
Volume | 1,824,704 | 4,960,247 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $155.80 |
52-Week Low | $72.47 | $116.74 |
Typical Hold Time | 66 Days | 111 Days |
Enterprise Value | $67.96B | $205.15B |
Dividend Yield | 2.36% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down slightly by 0.06% on the day, with a bearish technical signal from moving averages. The company shows solid profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027, while analyst consensus leans positive with 49% buy ratings.
The outlook is mixed: cost-cutting and brand investments support a turnaround, but declining 2026 revenue and net income projections pose risks. Valuation ratios like P/E of 27.19 suggest premium pricing, requiring execution success to justify. Key risks include U.S. market challenges and regulatory scrutiny in regions like India.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
